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Screening of human preimplantation embryos for numerical chromosome abnormalities has been conducted mostly at the preimplantation stage
using ﬂuorescence in situ hybridization. However, it is clear that preimplantation genetic screening (PGS) as it is currently practiced does not
improve live birth rates. Therefore the ESHRE PGS Task Force has decided to start a proof of principle study with the aim of determining
whether biopsy of the ﬁrst and second polar body followed by subsequent analysis of the complete chromosome complement of these polar
bodies using an array based technique enables a timely identiﬁcation of the chromosomal status of an oocyte. If the principle of this approach
can be proven, it is obvious that a multicentre randomized controlled trial should then be started to determine the clinical value of this technique.
In this way the ESHRE PGS Task Force hopes to redirect preimplantation screening from the blind alley to the main road of assisted reproduction.
One of the presumed factors causing low pregnancy rates in medically
assisted reproduction is the presence of chromosomal abnormalities
in preimplantation embryos. Therefore many centres have tried to
improve their results by screening human preimplantation embryos
for numerical chromosome abnormalities at the cleavage stage using
ﬂuorescence in situ hybridization (FISH) (Goossens et al., 2009).
Initially many low-level evidence studies (Gianaroli et al., 1999;
Munne et al., 1999) suggested a favourable outcome of preimplanta-
tion genetic screening (PGS) of aneuploidy on implantation and preg-
nancy rates, but more recent high-level evidence from randomized
control trials has not conﬁrmed these initially promising ﬁndings.
There are now 10 RCTs applied to both good (Jansen et al., 2008;
Mersereau et al., 2008; Staessen et al., 2008; Meyer et al., 2009)
and poor prognosis patients (Staessen et al., 2004; Stevens et al.,
2004; Debrock et al., 2007; Mastenbroek et al., 2007; Hardarson
et al., 2008;Schoolcraft et al., 2009). These studies have all shown
that PGS has not improved the delivery rate compared with a
control group, and some of these studies have shown harm or had
to be terminated prematurely. Meta-analysis of these trials shows a
statistically signiﬁcant reduction of ongoing pregnancies after PGS
[ongoing pregnancy rate per cycle of 13% (92 out of 696) after PGS
versus 21% (132 out of 638) in the control group; odds ratio 0.56,
95% CI 0.42–0.76; Mastenbroek et al., 2008]. Both the American
Society of Reproductive Medicine and the British Fertility Society
have concluded that PGS, as it is currently practiced, does not
improve the live birth rates in patients with advanced maternal age,
recurrent implantation failure or recurrent pregnancy loss (Anderson
and Pickering, 2008; ASRM, 2008). For the observed discrepancy
between the theory and the practice a number of reasons have
been put forward, such as inexperience in embryo testing, the insufﬁ-
cient number of chromosomes tested and the harm caused by the
biopsy procedure (Cohen et al., 2007; Handyside and Thornhill,
2007). However, most probably chromosomal mosaicism in cleavage-
stage embryos is the major factor (Coonen et al., 1994; Harper et al.,
1995; Delhanty et al., 1997; Coonen et al., 2004; Baart et al., 2006;
Mastenbroek et al., 2007; Vanneste et al., 2009). Thus, in many
cases, the biopsied and analysed blastomere is not representative
for the rest of the embryo. As an alternative, trophectoderm biopsy
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and increase the possibility of an accurate result as more cells can
be analysed from the same embryo. A recent trial by the Sydney
group on trophoblast PGS was terminated early since an interim
analysis indicated it was not possible to show an advantage for PGS
(Jansen et al., 2008).
Since mosaicism is not present at the zygote stage it seems to be
preferable to opt for polar body biopsy. The disadvantage of polar
body biopsy is, of course, that only the maternal aneuploidies can
be studied (Verlinsky et al., 1995). However, the vast majority of
human aneuploidies (more than 90%) are maternal (Nicolaidis and
Petersen, 1998). Moving towards the polar body biopsy has the
additional advantage that more time is available to study all the
chromosomes using novel molecular techniques (microarray CGH,
MLPA, etc.) after whole genome ampliﬁcation (Handyside et al.,
2004; Spits et al., 2006). This might circumvent the problem that, by
the application of FISH, the full chromosomal complement never
can be studied in an efﬁcient and reliable way.
Comprehensive chromosomal analysis of single cells from human
preimplantation embryos using whole genome ampliﬁcation and
single cell comparative genomic hybridization was introduced about
10 years ago (Voullaire et al., 2000; Wells and Delhanty, 2000).
Until very recently, the technology was time consuming, and biopsied
Day 3embryos needed to be frozen pending the results of the CGH,
with associated compromise in embryo quality (Wilton et al., 2001;
Munne and Wells, 2003). However, microarray-based methods will
yield similar results and may be sufﬁciently rapid to permit comprehen-
sive screening without the need for embryo cryopreservation. The
Cambridge based company BlueGnome has elaborated an array-based
CGH protocol which allows for analysis of all chromosomes from
biopsied polar bodies within 11–13 h. Therefore the ESHRE PGS
Task Force has decided to start a proof of principle study using
their methods with the aim of determining whether biopsy of the
ﬁrst and second polar body, followed by subsequent analysis of the
complete chromosome complement of these polar bodies using an
array-based technique, enables a timely identiﬁcation of the chromo-
somal status of an oocyte.
The speciﬁc objectives of this study are:
(i) To show that the analysis of both polar bodies can be completed
within a time period that allows for fresh transfer;
(ii) To ensure the reliable identiﬁcation of the chromosomal status of
an oocyte in at least 90% of polar body biopsy attempts;
(iii) To test the feasibility of a multicentre randomized trial based on
the technology used in the pilot study.
The polar bodies will be biopsied by the centres in Bonn (Germany)
and Bologna (Italy), since they have a documented and proven history
in the clinical application of this method and the experienced and
trained personnel required for a proof of principle. Both centres
have obtained ethical approval. The study aims to include 500
oocytes, independent from the number of patients. Assuming that
300 oocytes will be fertilized after ICSI, 600 polar bodies will be pro-
cessed for chromosomal diagnosis.
Expecting a 50% aneuploidy rate, another 150 aneuploid oocytes
will be processed for array analysis to verify the data obtained from
the polar bodies. In addition, undiagnosed oocytes will also be ana-
lysed but only if the resulting embryos are not transferred. There
will be no limitation regarding the number of patients recruited per
study site and no restriction on the maternal age of the patients
which will be included. First and second polar body will be separately
processed for chromosomal analysis. Chromosomal analysis of ﬁrst
and second polar bodies will be done at each study site using the
SurePlex ampliﬁcation protocol and the 24sure analysis provided by
BlueGnome (see http://www.bluegnome.co.uk/). The images will
be scored by two independent observers in each centre. In case of
discordance between the two observers the result will be categorized
as ‘unknown’. To estimate the concordance of the data from the polar
bodies and the corresponding oocytes, there will be a blind analysis of
those oocytes which are presumed to be aneuploid based on the
result of the chromosomal analysis of their polar bodies.
All data (patient and cycle data as well as array data) from both
study sites (polar bodies and oocytes) will be evaluated by an
independent data analysis team at the University of Amsterdam.
The concordance analysis will be made on the basis of the three cat-
egories euploid/aneuploid/unknown (the aim is to have at least 90%
concordance).
The study will start in October 2009 and the acquisition of the data
from the intended number of biopsied oocytes should be reached by
the beginning of 2010. Hopefully the ﬁrst data can be presented at the
26th Annual Meeting of ESHRE in Rome 2010. If the principle of this
approach can be proven, it is obvious that a multicentre randomized
controlled trial should be started along the same lines. With this
approach the ESHRE PGS Task Force hopes to redirect preimplanta-
tion screening from the blind alley back to the main road of assisted
reproduction.
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